conducted a retrospective analysis of immunotherapy plus chemotherapy data from 130 stage IIIA-IVB NSCLC patients and developed a PFS prediction nomogram based on bone metastasis, the dNLR, smoking status, and PD-L1 expression. This evidence concerns the gene CD274 and bone metastasis.